Colchicine-Placebo

DRUG2 trials

Sponsors

Population Health Research Institute

Conditions

Atherosclerosis of ExtremitiesInflammationNon ST Elevation Myocardial InfarctionPeripheral Arterial DiseaseST Elevation Myocardial Infarction

Phase 3

Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

CompletedNCT03048825

Population Health Research InstituteNon ST Elevation Myocardial Infarction, ST Elevation Myocardial Infarction

Start: 2018-02-01End: 2024-08-09Updated: 2024-10-15

Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

RecruitingNCT04774159

Population Health Research InstituteAtherosclerosis of Extremities, Inflammation, Peripheral Arterial Disease

Start: 2021-05-06End: 2029-12-01Target: 6150Updated: 2026-03-24

Related Papers

Colchicine in Acute Myocardial Infarction

New England Journal of Medicine2024-11-17204 citations

Routine Spironolactone in Acute Myocardial Infarction

New England Journal of Medicine2024-11-1731 citations

Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarction.

2024-06-2525 citations

Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease

Journal of Interventional Cardiology2024-03-1217 citations

The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose Colchicine 2 (LoDoCo2) Trial

Clinical Drug Investigation2022-10-0818 citations